We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Netscientific Plc | LSE:NSCI | London | Ordinary Share | GB00BN4R5Q82 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 69.00 | 68.00 | 70.00 | 69.00 | 67.75 | 69.00 | 14,092 | 08:00:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 1M | -3.09M | -0.1312 | -5.26 | 16.27M |
Date | Subject | Author | Discuss |
---|---|---|---|
06/1/2023 16:38 | PDSB recovering - 12.24 | blakieboy7 | |
06/1/2023 15:46 | Have to say it is quite unbelievable that ProAxis still haven't updated their website with the 3/4 new products. There was mention of a new site but shocking that with all the new hires and expansion they miss the basics. | loafofbread | |
06/1/2023 13:04 | Looks like ProAxis is finally ready to showcase itself. JPMorgan Healthcare is the place to be and you might notice they now have offices in Rockville USA. Looking forward to the annual update (last year 6th Jan) ProAxsis @ProAxsis · 3h Please email info@proaxsis.com to schedule a meeting at JPM, or for any other further information. #healthcare #JPMconference #proteases #biomarkers #assaydevelopment #invitrodiagnostics #diseasemanagement #respiratorydisease #bonehealth ProAxsis @ProAxsis · Dec 14, 2022 Christmas is approaching so place your orders now for a timely delivery for Q1 or even sooner. 2022 saw our company grow with Head Office doubling in size and the launch of new key products. We will continue to build on this with all our partners, current and new in 2023! | loafofbread | |
06/1/2023 10:48 | When there was buy of 600 shares the price did not move. When there was a sell of 900 shares the price was then marked down by 1 p. What kinds of market makers are there? | kingston78 | |
05/1/2023 09:26 | Agreed Dave, so frustrating. This should easily be over 80p now | blakieboy7 | |
05/1/2023 09:24 | All these buys yet the share price is only up by 2p. Had they been sells, the share price would probably have declined by much more. Typical NSCI. | investordave | |
05/1/2023 08:42 | You would think so with PDSB back up to $12. | loafofbread | |
05/1/2023 08:12 | Expecting this to move up today | blakieboy7 | |
04/1/2023 21:34 | PDSB has closed up 12.9% to US$ 12, recouping most of the previous day's loss on profit taking. | kingston78 | |
04/1/2023 17:38 | Don't worry. Nature will take its course. Share price manipulation works only for a short period of time. Value will prevail. | kingston78 | |
04/1/2023 15:39 | Someone is manipulating the share price marking it down by so much on low volume. | kingston78 | |
04/1/2023 15:34 | Corporate broker WH Ireland (WHI) used a piece of important news flow to re-look at the potential and valuations of the NetScientific PLC (AIM:NSCI)’s (NSCI) investments. On Tuesday, NSCI investee company PDS Biotechnology Corporation (NASDAQ:PDSB) inked a licence deal with Merck KGaA worth an upfront US$5mln. It will also be entitled to up to US$11mln in development and regulatory milestone payments, and up to US$105mln in commercial milestones, as well as a 10% royalty on future sales of PDS-developed M9241. In the wake of the announcement, WHI said in a note: “We see our risked-based SOTP [sum-of-the-parts] analysis of NSCI’s overall portfolio holdings yielding a fair value of 200p, and we highlight that NSCI’s holding in PDS Biotechnology now has a realisable value of around £13mln, ca 70% of NSCI’s market valuation.” The shares are currently changing hands for 76p each. NetScientific leverages its expertise in life sciences, healthcare, sustainability, and technology to invest in, develop, and commercialise promising companies. | loafofbread | |
04/1/2023 15:21 | PDSB is up 6% so far | blakieboy7 | |
03/1/2023 18:34 | Listening to the call makes it sound like an excellent deal. No idea why anyone would sell. | loafofbread | |
03/1/2023 15:42 | The PDSB share price appears to be in freefall today but hopefully just profit taking after a good run. | investordave | |
03/1/2023 14:14 | Genincode Plc (GENI) was up by 30% in early morning but I didn't buy it. No one has a bottomless pocket. Anyway, it is now up by 170% because of its approval of a licence agreement in California. If sufficient number of buyer push up the price you can see such a dramatic effect in a share such as GENI. This is an example that the same may happen to NSCI. Short sighted investors make a few pence in NSCI by selling. What a pity! They may lose that gain by jumping into another share (the spread in bid/ask is against the investor). | kingston78 | |
03/1/2023 13:47 | Fantastic piece of news from PDSB. It seems some are frightened to make money and are out like a shot on a couple of pence uplift. Suspect this has a good chance at doubling and some in 2023 not going anywhere IMHO | senttothegallows | |
03/1/2023 13:32 | Dr Ilian Iliev, CEO of NetScientific, also commented:"This is another important milestone in PDS' development, working with leading global pharma companies in enhancing its platform and pipeline commercial potential. After a successful 2022, the PDS team is off to a great start for 2023." | blakieboy7 | |
03/1/2023 12:29 | The share chart is bullish on any timescale (1 day, 1 month, 3 months, 6 months, 1 year, 3 years etc). This is what I call unstoppable. Currently, the upper band of the present cycle is at around 135 p. Therefore, my conservative projection of 110 p will be achieved comfortably . | kingston78 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions